PubHawk
Am Heart J May 2021 PMID 33470195

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.

StephenJ Nicholls, A Michael Lincoff, Harold E Bays, Leslie Cho, Diederick E Grobbee, John Jp Kastelein, Peter Libby, Patrick M Moriarty, Jorge Plutzky, Kausik K Ray, Paul D Thompson, William Sasiela, Denise Mason, Jaclyn McCluskey, Deborah Davey

Download social card

Mentions

66
Peak: 11 in Mar 2023
across 4 sources since Oct 2020

Extended reach

334,628
potential audience

Total likes

507

Video views

58,880

Mentions per month

Oct 2020 – Jul 2024

Where it's discussed

  • News32 articles
  • X / Twitter30 posts
  • YouTube2 videos
  • Blogs2 articles

AI synopsis

What people are saying

Several posts underscore the trial as a pivotal development in lipid therapy, with phrases like 'Great to see a large trial assessing new treatments' and 'Results expected soon,' indicating anticipation and perceived importance. The tone varies from informative to optimistic, with some posts referencing the trial's methodology and its potential to change clinical practices, which reflects both high interest and recognition of its impact.

AgreementModerate agreement

Most discussions seem to support the relevance and importance of the trial, with some emphasizing its role in evaluating new treatments for statin intolerance and cardiovascular risk reduction.

InterestHigh interest

The posts demonstrate high curiosity, highlighting the trial's design, endpoints, and potential impact on patient care, indicating strong engagement from the community.

EngagementModerate engagement

While some posts briefly mention facts about the trial and contextual information, others delve into detailed aspects like study design and future results, showing moderate to deep engagement.

ImpactModerate impact

The discussions recognize the trial's significance in advancing cardiovascular therapy options, though some posts focus more on informational updates than on discussing broader implications.

Abstract in brief

  • The CLEAR Outcomes trial investigates whether bempedoic acid, a liver-activated medication that lowers cholesterol without causing muscle side effects, can reduce cardiovascular events in patients with statin intolerance and existing or high risk of heart disease.
  • The study design is a large, randomized, double-blind, placebo-controlled trial involving over 14,000 patients, focusing on a primary endpoint of serious cardiovascular events like death, heart attacks, strokes, or revascularization procedures, with results expected after observing around 1,620 such events.
  • The trial aims to show if daily bempedoic acid can decrease adverse cardiovascular outcomes over a median of about 42 months, filling a knowledge gap about its effect on heart health beyond cholesterol lowering.
Read the full abstract

Top posts

Most liked on X and Bluesky
Michael Honigberg, MD, MPP
@mchonig · X

Excited for CLEAR Outcomes kicking off #ACC23 LBCTs this Saturday N=14,014 w/ ASCVD or high risk, LDL-C >=100, statin intolerance: https://t.co/rcOm2pzCr9 @pnatarajanmd & I summarized trials to date of bempedoic acid

Mar 2, 2023 · 36 likes · 7 shares · 2,906 followers View post →
Konstantin Krychtiuk
@krychtiukmd · X

CLEAR OUTCOMES trial testing bempedoic acid in statin-intolerant patients meets primary endpoint! Should be presented in Q1 2023. Study design: https://t.co/FRdVV5Zjhy 4-point MACE, design requires at least half of endpoints to be within the 3p MACE. https://t.co/myNjUc0GcM

Dec 7, 2022 · 17 likes · 5 shares · 6,299 followers View post →
cardio-met
@cardiomet_CE · X

8) #CLEAR_OUTCOMES is the latest in a series--The Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen--studies, designed to eval the effectiveness of #bempedoic_acid in #cholesterol management. See https://t.co/oGfCnqU1Iz: https://t.co/KaeTwti0qM

Mar 4, 2023 · 4 likes · 2 shares · 4,166 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

Statine sind keine #Pfefferminzbonbon. Statine schützen vor Herzinfarkten und Schlaganfällen, Pfefferminzbonbons machen Karies und Adipositas @dgfn_ev @YoungDgk @floriancustodis @StephanSchirmer1 @UllmannMdB https://t.co/tyH70NR0I9 https://t.co/0dLMyWxtC4 https://t.co/eZOeveabwi

Jul 10, 2024 · 4 likes · 1 share · 2,404 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

(Ab) Freitag 19:30 bei MARKUS@HOMe: Statine bei älteren Menschen? Professor Ulrich Laufs (Leipzig) Moderation: Sandra Schütze (Frankfurt) und @StephanSchirme1 Partner @dgfn_ev @oegnephro https://t.co/Z1keP3MDLD via @YouTube

Jan 25, 2023 · 3 likes · 1 share · 2,404 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

Zum Tag des Cholesterins unsere "Best of Lipidology" auf MARKUS @ HOMe (alle in Deutsch) https://t.co/Z1keP3M5W5 https://t.co/Bj6ZpnxS5x https://t.co/guTx84RdhF https://t.co/XfxMmCWfnM https://t.co/S4WH0jZWcQ

Jun 15, 2023 · 2 likes · 1 share · 2,404 followers View post →

All mentions

Florian Custodis
@floriancustodis · X

RT @gunnar_heine: Statine sind keine #Pfefferminzbonbon. Statine schützen vor Herzinfarkten und Schlaganfällen, Pfefferminzbonbons machen K…

Jul 11, 2024 · 1 share · 747 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

Statine sind keine #Pfefferminzbonbon. Statine schützen vor Herzinfarkten und Schlaganfällen, Pfefferminzbonbons machen Karies und Adipositas @dgfn_ev @YoungDgk @floriancustodis @StephanSchirmer1 @UllmannMdB https://t.co/tyH70NR0I9 https://t.co/0dLMyWxtC4 https://t.co/eZOeveabwi

Jul 10, 2024 · 4 likes · 1 share · 2,404 followers View post →
Stephan Schirmer
@StephanSchirme1 · X

RT @gunnar_heine: LDL senken, Herzinfarkte senken. Natürlich auch in der Primärprophylaxe. Natürlich auch bei älteren Menschen. https://t.c…

Jul 6, 2024 · 1 share · 18 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

LDL senken, Herzinfarkte senken. Natürlich auch in der Primärprophylaxe. Natürlich auch bei älteren Menschen. https://t.co/NvpChcMn7U @dgfn_ev @YoungDgk https://t.co/Gjd9NqCiIT via @NZZ

Jul 6, 2024 · 1 like · 1 share · 2,404 followers View post →
Florian Custodis
@floriancustodis · X

RT @gunnar_heine: Zum Tag des Cholesterins unsere "Best of Lipidology" auf MARKUS @ HOMe (alle in Deutsch) https://t.co/Z1keP3M5W5 https://…

Jun 15, 2023 · 1 share · 747 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

Zum Tag des Cholesterins unsere "Best of Lipidology" auf MARKUS @ HOMe (alle in Deutsch) https://t.co/Z1keP3M5W5 https://t.co/Bj6ZpnxS5x https://t.co/guTx84RdhF https://t.co/XfxMmCWfnM https://t.co/S4WH0jZWcQ

Jun 15, 2023 · 2 likes · 1 share · 2,404 followers View post →
Luis Paredes
@LParedes7972 · X

RT @cardiomet_CE: 8) #CLEAR_OUTCOMES is the latest in a series--The Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen--stu…

Mar 4, 2023 · 2 shares · 172 followers View post →
Ahmed Mohsen
@drahmedmohsen85 · X

RT @cardiomet_CE: 8) #CLEAR_OUTCOMES is the latest in a series--The Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen--stu…

Mar 4, 2023 · 2 shares · 23,165 followers View post →
cardio-met
@cardiomet_CE · X

8) #CLEAR_OUTCOMES is the latest in a series--The Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen--studies, designed to eval the effectiveness of #bempedoic_acid in #cholesterol management. See https://t.co/oGfCnqU1Iz: https://t.co/KaeTwti0qM

Mar 4, 2023 · 4 likes · 2 shares · 4,166 followers View post →
Ritu Thamman MD
@iamritu · X

RT @mchonig: Excited for CLEAR Outcomes kicking off #ACC23 LBCTs this Saturday N=14,014 w/ ASCVD or high risk, LDL-C >=100, statin intoler…

Mar 3, 2023 · 7 shares · 31,744 followers View post →
Rohan Bhattacharya
@rohanbme · X

RT @mchonig: Excited for CLEAR Outcomes kicking off #ACC23 LBCTs this Saturday N=14,014 w/ ASCVD or high risk, LDL-C >=100, statin intoler…

Mar 2, 2023 · 7 shares · 555 followers View post →
Joshua Levenson, MD
@jelevenson · X

RT @mchonig: Excited for CLEAR Outcomes kicking off #ACC23 LBCTs this Saturday N=14,014 w/ ASCVD or high risk, LDL-C >=100, statin intoler…

Mar 2, 2023 · 7 shares · 4,093 followers View post →
Dr Anastasia Mihailidou FAHA FCSANZ FESC
@AnastasiaSMihai · X

RT @mchonig: Excited for CLEAR Outcomes kicking off #ACC23 LBCTs this Saturday N=14,014 w/ ASCVD or high risk, LDL-C >=100, statin intoler…

Mar 2, 2023 · 7 shares · 19,315 followers View post →
Andrew J Sauer MD
@AndrewJSauer · X

RT @mchonig: Excited for CLEAR Outcomes kicking off #ACC23 LBCTs this Saturday N=14,014 w/ ASCVD or high risk, LDL-C >=100, statin intoler…

Mar 2, 2023 · 7 shares · 19,409 followers View post →
Dr. Martha Gulati ♥️
@DrMarthaGulati · X

RT @mchonig: Excited for CLEAR Outcomes kicking off #ACC23 LBCTs this Saturday N=14,014 w/ ASCVD or high risk, LDL-C >=100, statin intoler…

Mar 2, 2023 · 7 shares · 64,871 followers View post →
Pradeep Natarajan
@pnatarajanmd · X

RT @mchonig: Excited for CLEAR Outcomes kicking off #ACC23 LBCTs this Saturday N=14,014 w/ ASCVD or high risk, LDL-C >=100, statin intoler…

Mar 2, 2023 · 7 shares · 25,447 followers View post →
Michael Honigberg, MD, MPP
@mchonig · X

Excited for CLEAR Outcomes kicking off #ACC23 LBCTs this Saturday N=14,014 w/ ASCVD or high risk, LDL-C >=100, statin intolerance: https://t.co/rcOm2pzCr9 @pnatarajanmd & I summarized trials to date of bempedoic acid

Mar 2, 2023 · 36 likes · 7 shares · 2,906 followers View post →
Florian Custodis
@floriancustodis · X

RT @gunnar_heine: (Ab) Freitag 19:30 bei MARKUS@HOMe: Statine bei älteren Menschen? Professor Ulrich Laufs (Leipzig) Moderation: Sandra…

Jan 26, 2023 · 1 share · 747 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

(Ab) Freitag 19:30 bei MARKUS@HOMe: Statine bei älteren Menschen? Professor Ulrich Laufs (Leipzig) Moderation: Sandra Schütze (Frankfurt) und @StephanSchirme1 Partner @dgfn_ev @oegnephro https://t.co/Z1keP3MDLD via @YouTube

Jan 25, 2023 · 3 likes · 1 share · 2,404 followers View post →
Ben Cole
@brwcole · X

RT @krychtiukmd: CLEAR OUTCOMES trial testing bempedoic acid in statin-intolerant patients meets primary endpoint! Should be presented in…

Dec 7, 2022 · 5 shares · 296 followers View post →
rafavidalperez
@rafavidalperez · X

RT @krychtiukmd: CLEAR OUTCOMES trial testing bempedoic acid in statin-intolerant patients meets primary endpoint! Should be presented in…

Dec 7, 2022 · 5 shares · 13,848 followers View post →
Hawaii Born
@hawaii_imua · X

RT @krychtiukmd: CLEAR OUTCOMES trial testing bempedoic acid in statin-intolerant patients meets primary endpoint! Should be presented in…

Dec 7, 2022 · 5 shares · 108 followers View post →
Dr. Purvi Parwani
@purviparwani · X

RT @krychtiukmd: CLEAR OUTCOMES trial testing bempedoic acid in statin-intolerant patients meets primary endpoint! Should be presented in…

Dec 7, 2022 · 5 shares · 39,789 followers View post →
LibKey
@libkey_io · X

@krychtiukmd @SABOURETCardio @pabeda1 @lipiddoc @CMichaelGibson @EsperionInc @purviparwani @ajnelson @MKIttlesonMD @DrMarthaGulati Get access rather than a paywall: https://t.co/gwoyeuaSw0 Add https://t.co/SXSePSX5De to the DOI URL when sharing articles to promote scholarly communication

Dec 7, 2022 · 555 followers View post →
Konstantin Krychtiuk
@krychtiukmd · X

CLEAR OUTCOMES trial testing bempedoic acid in statin-intolerant patients meets primary endpoint! Should be presented in Q1 2023. Study design: https://t.co/FRdVV5Zjhy 4-point MACE, design requires at least half of endpoints to be within the 3p MACE. https://t.co/myNjUc0GcM

Dec 7, 2022 · 17 likes · 5 shares · 6,299 followers View post →
JoAnne Foody, MD, FACC, FAHA
@FoodyMD · X

@kevinnbass @antoniotherose Largest outcomes trial to assess an oral option for patients unable to take statins! Results 1Q2023. Stay tuned! Rationale and design of the CLEAR-outcomes trial: Evaluating the effec... https://t.co/y9Iby0B3rQ #bempedoicacid

May 30, 2022 · 1 like · 1,754 followers View post →
Hilly Paige Jr
@hillypaige2 · X

Excellent review on novel #lipid therapies by @JTWilkinsMD and @dmljmd. Clarification for #BempedoicAcid, there is an ongoing outcome study - CLEAR Outcomes, which was not mentioned. Results likely in 2022/2023. https://t.co/tuQCwiHAUD @ProfSNicholls @ProfKausikRay @FoodyMD https://t.co/0HSua3DIfH

Jul 26, 2021 · 1 like · 1,110 followers View post →
Dataemia
@Dataemia · X

(Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance.) https://t.co/tfxGjvtMzu

Jan 22, 2021 · 965 followers View post →
pallavi mishra
@drpallaviojha · X

Rationale and design of the CLEAR-outcomes trial: Evaluating the effec... https://t.co/P5VOBeVzYj

Jan 1, 2021 · 1 like · 117 followers View post →
Daniel Mark
@DanMarkMD · X

RT @AmericanHeartJ: In Press: Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular e…

Oct 28, 2020 · 2 shares · 2,996 followers View post →